PC161B-HA07

PC161B-HA07 is a pediatric oral suspension formulation of **levocetirizine dihydrochloride**, developed by Guangzhou Yipinhong Pharmaceutical (also known as Apichope). Levocetirizine is a third-generation, non-sedating antihistamine that acts as a highly selective and potent antagonist of peripheral H1 receptors. As the active R-enantiomer of cetirizine, it provides relief from allergic symptoms with a reduced risk of central nervous system side effects compared to first-generation antihistamines. This specific suspension formulation is part of Yipinhong's specialized pediatric drug technology platform, designed to improve dosing accuracy and patient compliance in children (ages 0-14) suffering from allergic conditions such as seasonal and perennial allergic rhinitis and chronic idiopathic urticaria.

Other names

Levocetirizine Dihydrochloride Oral Suspension